Vericel Corporation

383 articles about Vericel Corporation

• Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance

  2/29/2024

  Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, reported financial results and business highlights for the fourth quarter and year ended December 31, 2023, and provided full-year 2024 financial guidance.

• Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024

  2/27/2024

  Vericel Corporation today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Tuesday, March 5, 2024.

• Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024

  2/15/2024

  Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024.

• Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024

  2/5/2024

  Vericel Corporation today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference.

• Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results

  1/9/2024

  Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results for the fourth quarter and year ended December 31, 2023.

• Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024

  1/3/2024

  Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 42nd Annual J.P. Morgan Healthcare Conference.

• Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

  11/8/2023

  Vericel Corporation today reported financial results and business highlights for the third quarter ended September 30, 2023.

• Vericel to Present at the Stephens Annual Investment Conference

  11/7/2023

  Vericel Corporation today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will present at the Stephens Annual Investment Conference.

• Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023

  10/25/2023

  Vericel Corporation today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023.

• Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid

  9/28/2023

  Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the recent publication of results from the Phase 3 DETECT study assessing the safety and efficacy of NexoBrid® (anacaulase-bcdb) in the Journal of Burn Care & Research.

• Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

  9/20/2023

  Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the U.S. commercial availability of NexoBrid® (anacaulase-bcdb) for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns.

• Vericel to Present at the Morgan Stanley Global Healthcare Conference

  9/6/2023

  Vericel Corporation today announced that Nick Colangelo, President and CEO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference at 7:30 a.m. ET on Tuesday, September 12, 2023.

• Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

  8/2/2023

  Vericel Corporation today reported financial results and business highlights for the second quarter ended June 30, 2023, and provided updated full-year 2023 financial guidance.

• Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023

  7/20/2023

  Vericel Corporation today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023.

• Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

  5/10/2023

  Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2023, and provided updated full-year 2023 financial guidance.

• Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023

  4/26/2023

  Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023.

• Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023

  2/28/2023

  Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference.

• Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance

  2/23/2023

  Vericel Corporation today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022, and provided full-year 2023 financial guidance.

• Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023

  2/9/2023

  Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter 2022 financial results on Thursday, February 23, 2023.

• Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program

  1/10/2023

  Vericel Corporation today announced preliminary, unaudited financial results for the fourth quarter and year ended December 31, 2022 and an accelerated launch timeline for MACI® arthroscopic delivery, which is now anticipated to be launched in 2024.